3-溴-4-氯呋喃并[3,2-c]吡啶 | 220939-72-0

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡啶类
• 中文名称: 3-溴-4-氯呋喃并[3,2-c]吡啶
• 中文别名: 3-溴-4-氯呋喃并[3,2-C]吡啶
• 英文名称: 4-chloro-3-bromofuro<3,2-c>pyridine
• 英文别名: 3-bromo-4-chlorofuro[3,2-c]pyridine；4-chloro-3-bromo-furo[3,2-c]pyridine
• CAS: 220939-72-0
• 化学式: C₇H₃BrClNO
• 分子量: 232.464
• InChiKey: VJWDCUWEVVDVKR-UHFFFAOYSA-N

物化性质

• 沸点：
  305.5±37.0 °C(Predicted)
• 密度：
  1.820±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Bromo-4-chlorofuro[3,2-c]pyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Bromo-4-chlorofuro[3,2-c]pyridine
CAS number: 220939-72-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H3BrClNO
Molecular weight: 232.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

3-溴-4-氯呋喃并[3,2-C]吡啶可用作有机合成中间体和医药中间体，主要应用于实验室研发及医药化工生产过程。

反应信息

• 作为反应物：
  描述：

  3-溴-4-氯呋喃并[3,2-c]吡啶 在 bis-triphenylphosphine-palladium(II) chloride 、 ammonium hydroxide 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 乙醇 、 水 、 甲苯 为溶剂， 反应 74.0h， 生成 6-(4-aminofuro[3,2-c]pyridin-3-yl)-N-phenyl-1-naphthamide
  参考文献：
  名称：

  NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF

  摘要：

  公开号：

  EP3112351B1
• 作为产物：
  描述：

  3-溴-呋喃[3,2-c]吡啶 在 间氯过氧苯甲酸 、 三氯氧磷 作用下， 以 二氯甲烷 、 氯仿 为溶剂， 反应 25.0h， 生成 3-溴-4-氯呋喃并[3,2-c]吡啶
  参考文献：
  名称：

  呋喃吡啶。XXVIII †。呋喃并[2,3-3-溴衍生物的反应b ] - ， - [3,2- b ] - ， - [2,3- Ç ] -和- [3,2- c ^ ]吡啶和它们的Ñ -氧化物

  摘要：

  3-溴呋喃并[2,3-的溴化b ] - 1A， - [3,2- b ] - 1B和- [3,2- c ^ ]吡啶1D，得到2,3-二溴衍生物2a，图2b和2d中， -[2,3- c ]-化合物1c没有给出二溴衍生物。硝化1a-d得到2-硝基-3-溴化合物3a-d。所述Ñ -oxides 4A-D的1A-d被提交到氰化三甲基甲硅烷氰化物，得到相应的α氰基吡啶化合物6A-d 。氯化用氧氯化磷的4a和4d主要产生氯吡啶衍生物7a，7′a和7d，而4b和4c主要产生氯呋喃衍生物7′b和7′c，伴随着氯吡啶衍生物7b，7′b和7c的形成。用乙酸酐对4a和4b进行乙酰氧基化，得到乙酰氧基吡啶化合物8a，8'a和8b，而4c和4d得到乙酰氧基吡啶8'c，8'd和8'd，吡啶酮8c和8d，乙酰氧基呋喃8'c和二溴化合物9c和9'c。

  DOI：

  10.1002/jhet.5570350602

文献信息

• [EN] HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS<br/>[FR] COMPOSÉS HÉTÉROAROMATIQUES ET LEUR UTILISATION COMME LIGANDS DE LA DOPAMINE D1
  申请人：PFIZER

  公开号：WO2014072881A1

  公开（公告）日：2014-05-15

  The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced β- arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses.

  本发明部分提供了化合物I的公式：及其药学上可接受的盐和N-氧化物；制备的过程和中间体；以及其组合物和用途。本发明进一步提供了具有减少D1R耐受性的D1激动剂，相对于多巴胺具有减少β-阿雷斯汀招募活性的D1激动剂，当结合到D1R时与D1R的Ser188显著相互作用但与Ser202的相互作用不显著的D1激动剂，当结合到D1R时与D1R的Asp103相互作用较弱并且与Ser198相互作用较弱的D1激动剂，以及它们的用途。
• Thienopyridine and furopyridine kinase inhibitors
  申请人：Betschmann Patrick

  公开号：US20050026944A1

  公开（公告）日：2005-02-03

  Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有以下化学式的化合物对抑制蛋白酪氨酸激酶具有用处。本发明还公开了制备这些化合物的方法、含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。
• Defining Structure–Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D₁ Receptor Agonists
  作者：Michael L. Martini、Jing Liu、Caroline Ray、Xufen Yu、Xi-Ping Huang、Aarti Urs、Nikhil Urs、John D. McCorvy、Marc G. Caron、Bryan L. Roth、Jian Jin

  DOI：10.1021/acs.jmedchem.9b00351

  日期：2019.4.11

  protein-coupled receptors (GPCRs) are capable of downstream signaling through distinct noncanonical pathways such as β-arrestins in addition to the canonical G protein-dependent pathways. GPCR ligands that differentially activate the downstream signaling pathways are termed functionally selective or biased ligands. A class of novel non-catechol G protein-biased agonists of the dopamine D1 receptor (D1R) was

  G蛋白偶联受体（GPCR）除通过G蛋白依赖性经典途径外，还能够通过不同的非经典途径（例如β-arrestin）进行下游信号传导。差异激活下游信号传导途径的GPCR配体称为功能选择性或偏向配体。最近公开了一类新型的多巴胺D1受体（D1R）的非儿茶酚G蛋白偏向的激动剂。我们进行了第一个全面的结构-功能选择性关系研究，测量了该支架的四个区域的GS和β-arrestin2募集活动，结果得到了50多个具有不同功能选择性谱的类似物。与起始化合物相比，某些化合物成为β-arrestin2募集的有效全效激动剂，而其他化合物则显示出更高的GS偏倚。具有改变的功能选择性特征的类似物的药代动力学测试表明，血脑屏障渗透性极佳。这项研究为研究D1R的配体偏倚提供了新颖的工具，并为开发下一代有偏向的D1R配体铺平了道路。
• Novel chemical compounds
  申请人：Miyazaki Yasushi

  公开号：US20080182868A1

  公开（公告）日：2008-07-31

  This invention relates to newly identified compounds for treating and preventing tumors and cancers, and methods for treating proliferative diseases associated with the imbalance or inappropriate activity of tyrosine kinases implicated in proliferative diseases.

  本发明涉及治疗和预防肿瘤和癌症的新型化合物，以及用于治疗与参与增殖性疾病的酪氨酸激酶失衡或不适当活性相关的增殖性疾病的方法。
• THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS
  申请人：Betschmann Patrick

  公开号：US20070155776A1

  公开（公告）日：2007-07-05

  Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有化学式的化合物对于抑制蛋白质酪氨酸激酶具有用处。本发明还公开了制备该化合物的方法、含有该化合物的组合物以及使用该化合物的治疗方法。